Observational studyArthritis & rheumatology (Hoboken, N.J.)2018
Observational study in Arthritis & rheumatology (Hoboken, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 162 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
Who cites it
162 citing papers in PubMed, 6 syntheses or guidelines pooled it, 330 citations in OpenAlex.
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.Annals of the rheumatic diseases · 2024Pooled it
- Pooled it
- ACR Appropriateness Criteria® Noncerebral Vasculitis.Journal of the American College of Radiology : JACR · 2021Guideline
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Guideline
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.Arthritis care & research · 2021Guideline
- F-18 FDG PET for assessment of disease activity of large vessel vasculitis: A systematic review and meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Pooled it
- Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritis.Arthritis research & therapy · 2026Trial
- Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis.Rheumatology (Oxford, England) · 2021Trial
- Home-Based Exercise Training in Childhood-Onset Takayasu Arteritis: A Multicenter, Randomized, Controlled Trial.Frontiers in immunology · 2021Trial
- Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.Arthritis & rheumatology (Hoboken, N.J.) · 2019Trial
- Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.Arthritis care & research · 2026Observational
- Aortitis as a High-Risk Vascular Syndrome: Integrating Phenotype-Driven Diagnosis, Multidisciplinary Assessment, and Personalised Management.Journal of personalized medicine · 2026Review
- Large vessel vasculitis reframed: integrating conceptual shifts and evidence into practice for Takayasu arteritis and giant cell arteritis.Journal of rheumatic diseases · 2026Review
- Article
- Toward a standardized and interoperable imaging biomarker catalog.Insights into imaging · 2026Article
- When Cancer Clots: An Extensive Radiologic Analysis of Cancer-Associated Thromboembolism.Cancers · 2026Review
- Article
- Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026Review
- Dynamic vascular changes on long-term ultrasound monitoring predict relapse in large-vessel giant cell arteritis.Arthritis research & therapy · 2026Article
- EACVI survey on the use of multi-modality cardiovascular imaging in immune-mediated inflammatory diseases.European heart journal. Imaging methods and practice · 2026Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo assess the clinical value of
methodsPatients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse.
resultsA total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85% (95% confidence interval [95% CI] 69, 94) and a specificity of 83% (95% CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58%]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55% versus 11%; P = 0.03) over a median follow-up period of 15 months.
conclusionFDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.